Menghis Bairu, is a physician, entrepreneur, coach, business executive, editor, author, and philanthropist. He has 30 plus years of international experience in the biotechnology, pharmaceutical, drug delivery and device, global health, and non-profit arenas.
Dr. Bairu is founder, chairman, and CEO of Proxenia Venture Partners, which provides capital, experienced management, and access to a global networks of experts to companies in early and late stage clinical development in biotechnology that address global challenges and improve patient lives. Most recently, he served as Executive Chairman of Treos Bio, a start-up company that uses computational biology to develop precision cancer immunotherapies tailored to patients' genetics. In addition, he is Founder and Chairman Emeritus of Serenus Biotherapeutics, an emerging market focused specialty biopharmaceutical company. In that role he raised up to $43 million in series A funding.
Dr. Bairu concurrently served as Executive Vice President, Chief Medical Officer, Head of Global Development for Elan and President/CEO of Speranza Therapeutics. As EVP and CMO, Dr. Bairu was member of the Elan’s Operating Committee. He successfully led corporate R&D due diligence processes that resulted in a transaction with J&J at a value of approximately $1.5 billion. In 2013, he also led corporate R&D due diligence resulting in the sale of Elan to Perrigo for $8.6 billion.
Prior to joining Elan, Dr. Bairu worked at Genentech for more than six years in several managed care, medical, and commercial roles (Rituximab, Herceptin, TNK, tPA, Growth Hormone). He also served on the board of directors of various companies, including One World Health, a non-profit drug development company funded by the Bill and Melinda Gates Foundation.
Dr. Bairu currently serves on various Boards (privately and publicly traded companies), I.e Chair, Risk Management committee/Board of Directors at https://cureblindness.org/, and is Adjunct Professor at the University of California, San Francisco School of Medicine where he lectures on global clinical trials’ design, development, and conduct. He is also Corporate Strategic Advisor to https://advanceprotein.com/, a US based company passionate about marine protein as a way forward for creating a green food security system and ending malnutrition.